Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study

Markus V. Heppt; Teresa Amaral; Katharina C. Kähler; Lucie Heinzerling; Jessica C. Hassel

doi:10.1186/s40425-019-0800-0

Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study

Markus V. Heppt, Teresa Amaral, Katharina C. Kähler, Lucie Heinzerling, Jessica C. Hassel, Markus Meißner, Nicole Kreuzberg, Carmen Loquai, Lydia Reinhardt, Jochen Utikal, Evelyn Dabrowski, Anja Gesierich, Claudia Pföhler, Patrick Terheyden, Kai‐Martin Thoms...

BMJ (2019) • Volume 7, Issue 1, Pages 299-299

PDF Available

Abstract

The tolerability of the combined checkpoint blockade in UM may possibly be better than in trials on cutaneous melanoma. This study implies that combined checkpoint blockade represents the hitherto most effective treatment option available for metastatic UM available outside of clinical trials.

Quick Actions

Read Full Paper

Publication Info

DOI

10.1186/s40425-019-0800-0

Language

English

Topic

Ocular Oncology and Treatments

Keywords

Medicine, Internal medicine, Ipilimumab, Oncology, Blockade, Adverse effect, Melanoma, Immune checkpoint, Retrospective cohort study, Progression-free survival, Cancer, Gastroenterology, Surgery, Immunotherapy, Overall survival, Cancer research

Published

November 13, 2019

Citations

136 citations

FWCI

18.32

External Resources

DOI Link OpenAlex

Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study

Abstract

Quick Actions

Publication Info

External Resources

Suggested Papers

Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS‐1): A multicenter, randomized, double‐blind, placebo‐controlled phase 3 trial

Three-year outcomes of post-acute sequelae of COVID-19

The chiropractic profession: a scoping review of utilization rates, reasons for seeking care, patient profiles, and care provided

Suggested Papers

Suggested Papers

Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS‐1): A multicenter, randomized, double‐blind, placebo‐controlled phase 3 trial

Three-year outcomes of post-acute sequelae of COVID-19

The chiropractic profession: a scoping review of utilization rates, reasons for seeking care, patient profiles, and care provided